分流治疗的正常压力脑积水患者的青光眼
正常眼压性青光眼组的中位保护期(发病至分流术时间)为12.0个月,无正常眼压性青光眼组为18.0个月(p = 0.033)。作者结论认为,视神经暴露于颅内压降低的持续时间是分流治疗正常压力脑积水患者发生正常眼压性青光眼的关键危险因素。
要点
- 22例分流治疗正常压力脑积水患者中9例患正常眼压性青光眼,患病率约升高40倍(p < 0.001)。
- 正常眼压性青光眼组中位保护期12.0个月,无正常眼压性青光眼组18.0个月(p = 0.033)。
- 正常眼压性青光眼组中位颅内压下降幅度乘以暴露月数为76.0 mmHg×月,无正常眼压性青光眼组为24.1 mmHg×月(p = 0.048)。
核心结论
- 分流治疗正常压力脑积水患者发生正常眼压性青光眼的关键危险因素是视神经暴露于颅内压降低的持续时间。
- 准备接受脑脊液分流术的正常压力脑积水患者应被告知发生青光眼的风险。
研究设计与样本
- 分析接受脑室腹腔分流术的正常压力脑积水患者数据。
- 纳入随访超过6个月、无颅内压变化或脑脊液动力学 disturbance 相关病变、无手术或阀门相关并发症的患者,安排眼科评估。
主要发现
- 22例患者中9例患有正常眼压性青光眼,患病率较无脑积水的普通老年人群约高40倍(p < 0.001)。
- 正常眼压性青光眼组中位保护期为12.0个月,无正常眼压性青光眼组为18.0个月(p = 0.033)。
- 正常眼压性青光眼组中位颅内压下降幅度乘以暴露月数为76.0 mmHg×月,无正常眼压性青光眼组为24.1 mmHg×月(p = 0.048)。
- 正常眼压性青光眼组中位调整年龄为85.1岁,无正常眼压性青光眼组为78.8岁(p = 0.001)。
临床怎么用
- 准备接受脑脊液分流术的正常压力脑积水患者应被告知发生青光眼的风险。
- 作者认为纵向研究可提供特定颅内压下降幅度下可耐受时间的估计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Changes in the pressure gradient between intraocular and intracranial compartments at the lamina cribrosa level are a possible explanation of normal tension glaucoma (NTG). Shunt-treated normal pressure hydrocephalus (NPH) is a model for testing whether the increase (time from disease onset to CSF shunt placement, i.e., "protection period") and decrease (time from shunt placement to observation, i.e., "exposure period") in intracranial pressure (ICP) are glaucoma protective or risk factors, respectively. The authors estimated the prevalence of NTG in patients with shunt-treated NPH and calculated the extent of optic nerve exposure to changes in the trans-lamina cribrosa gradient. METHODS: Data obtained in patients with NPH who had undergone ventriculoperitoneal (VP) shunt placement were analyzed. Patients with more than 6 months' follow-up, no pathologies associated with ICP changes or CSF dynamics disturbances, and no surgical or valve-related complications were scheduled for ophthalmic evaluation. RESULTS: Nine of 22 patients had NTG, which is about a 40-fold increase in rate compared with the rate in the general elderly population without hydrocephalus (p < 0.001). The median protection period was 12.0 months in patients with NTG and 18.0 months in those without NTG (p = 0.033). The median ICP decrease multiplied by duration of exposure in months was 76.0 mm Hg × months in the NTG group and 24.1 mm Hg × months in the no-NTG group (p = 0.048). The patients' median adjusted age (adjusted for "protection" and "exposure" times) was 85.1 years in the NTG group and 78.8 years in the no-NTG group (p = 0.001). CONCLUSIONS: A crucial risk factor for development of NTG in patients with shunt-treated NPH is the duration of optic nerve exposure to the lowering of ICP. Patients with NPH who are candidates for CSF shunting should be informed of the risk of incurring glaucoma. Longitudinal studies could provide estimates of tolerated times for a given ICP decrease.
引用
- Gallina P, Savastano A, Becattini E, et al. Glaucoma in patients with shunt-treated normal pressure hydrocephalus. J Neurosurg. 2017. PMID: 29148901. doi:10.3171/2017.5.JNS163062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。